Cover Image
Market Research Report

Emerging Pharmaceutical Market in Brazil - Regulatory Framework Forces MNCs to Partner with Local Players Resulting in Profit and Control Sharing

Published by GBI Research Product code 245747
Published Content info 81 Pages
Immediate Delivery Available
Price
Back to Top
Emerging Pharmaceutical Market in Brazil - Regulatory Framework Forces MNCs to Partner with Local Players Resulting in Profit and Control Sharing
Published: July 1, 2012 Content info: 81 Pages
Description

Summary

GBI Research's new report, "Emerging Pharmaceutical Market in Brazil - Regulatory Framework Forces MNCs to Partner with Local Players Resulting in Profit and Control Sharing" provides an in-depth analysis of the trends, issues and challenges in the pharmaceutical market in Brazil. The report analyzes the overall pharmaceutical and outsourcing market structure of the country. The report provides competitive benchmarking for the leading companies and analyzes the M&A and strategic partnerships that shape the Brazilian pharmaceutical market. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

The Brazilian pharmaceutical market is one of the top emerging markets globally. In terms of revenue it is the seventh largest market in the world and the largest in Latin America. Since the introduction of the new Patent Law in 1997, many foreign pharmaceutical companies have entered the Brazilian market. However, due to the lack of government support in the country, these companies (MNCs) have mostly partnered with local players for the expansion of their services.

GBI Research analysis shows that generics have achieved higher growth in the market due to legal and regulatory support. The generics accounted for 20.6% of the market share in 2011 and are expected to grow in future. Both private and public sectors are playing a role in the healthcare infrastructure of the country. The availability of reasonably priced raw materials and good access to the patient pool, well-equipped facilities, high-quality staff and infrastructure are the major attractions for foreign players.

The Brazilian pharmaceutical market grew at a CAGR (Compound Annual Growth Rate) of 9% between 2004 and 2010. The economic growth of the country was above the world average and inflation was low compared to Argentina and Paraguay. In accordance with the Brazilian Ministry of Health, the private healthcare sector contributes approximately 2% of Brazil's GDP.

According to GBI Research's analysis, the Brazilian pharmaceutical market poses a number of challenges due to its diverse nature, which creates difficulties in terms of understanding the characteristics of sub-regions. The major challenge for foreign players planning to enter the market is the legal framework of the country. This forces the companies into partnering with local companies, resulting in profit and control sharing. The legal and regulatory framework for patents is limited, leading to a lack of protection for intellectual property rights. This tends to result in difficulties for companies spending on R&D.

Scope

  • The overall pharmaceutical, biotech and outsourcing market structure in Brazil
  • A market characterization of the Brazilian pharmaceutical market, including market size, major regulatory bodies, pricing and reimbursement issues, major distribution channels and intellectual property rights.
  • Brazilian CRO market growth
  • Analysis of the leading segments within the Brazilian pharmaceutical industry
  • Market drivers and restraints that have a significant impact on the market.
  • Competitive benchmarking of the leading companies in the pharmaceutical and CRO markets.
  • Key M&A activities and strategic partnership deals that have taken place between 2004 and mid-2011.

Reasons to buy

  • Develop market-entry and market expansion strategies by identifying the leading emerging markets poised for strong growth.
  • Develop a tailored country strategy through the understanding of key drivers and barriers of each country's pharmaceutical market.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
Table of Contents
Product Code: GBIHC190MR

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

3. Emerging Pharmaceutical Market: Brazil - Industry Characterstics

  • 3.1. Market Size and Market Forecast
  • 3.2. Market Share by Therapy Area
  • 3.3. Branded versus Generic Market Share
  • 3.4. R&D Expenditure Innovations
    • 3.4.1. Increased Screening Rates during R&D
  • 3.5. Top Pharmaceutical Companies in Brazil
    • 3.5.1. Domestic Players
    • 3.5.2. Foreign Players
  • 3.6. Drivers and Challenges
    • 3.6.1. Drivers
    • 3.6.2. Barriers
  • 3.7. Healthcare Delivery System
    • 3.7.1. Brazil Healthcare Delivery Opportunities
    • 3.7.2. Brazil Healthcare Delivery Challenges
  • 3.8. PESTLE Analysis
    • 3.8.1. Political factors
    • 3.8.2. Economic factors
    • 3.8.3. Social factors
    • 3.8.4. Technological factors
    • 3.8.5. Legal factors
    • 3.8.6. Environmental factors

4. Emerging Pharmaceutical Market: Brazil - Macroeconomic Environment

  • 4.1. Demographic Analysis
    • 4.1.1. Population Size, Growth, and Structure
    • 4.1.2. Disease Overview in Brazil
  • 4.2. GDP
  • 4.3. Per Capita Income
    • 4.3.1. Context
    • 4.3.2. Analytical Framework
  • 4.4. Healthcare Expenditure
    • 4.4.1. Context
    • 4.4.2. Analytical Framework
  • 4.5. Healthcare Infrastructure
    • 4.5.1. Analytical Framework

5. Emerging Pharmaceutical Market: Brazil -Healthcare Regulation

  • 5.1. Pharmaceutical Regulation in Brazil
  • 5.2. Drug Approval Process
  • 5.3. Drug Registration Process
  • 5.4. Patents and Generics (IPR)
  • 5.5. Health Insurance Coverage
  • 5.6. Clinical Trials
    • 5.6.1. Context
    • 5.6.2. Analytical Framework
  • 5.7. Pricing and Reimbursement
    • 5.7.1. Private Insurance
    • 5.7.2. Hospotels
    • 5.7.3. Cosmetic Travel
  • 5.8. Regulatory Bodies
    • 5.8.1. Ministry of Health (MOH)
    • 5.8.2. Unified Health System (UHS also called as SUS in Brazil)

6. Emerging Pharmaceutical Market: Brazil - Industry Trends

  • 6.1. Mergers and Acquisitions
    • 6.1.1. M&A Deals by Year
    • 6.1.2. Deal by Value
    • 6.1.3. Recent M&A Deals
    • 6.1.4. Top Five M&As
  • 6.2. Co-development Deals
    • 6.2.1. Deals by Year
    • 6.2.2. Deal by Value
    • 6.2.3. Recent Co-development Deals
    • 6.2.4. Top Co-development Deals
  • 6.3. Licensing Agreements
    • 6.3.1. Deals by Year
    • 6.3.2. Deals by Value
    • 6.3.3. Recent Licensing Agreements
    • 6.3.4. Top Licensing Agreements

7. Emerging Pharmaceutical Market: Brazil - CRO Industry

  • 7.1. Contract Research Organization (CRO) Market Size and Growth
    • 7.1.1. PPD
    • 7.1.2. PRA International
    • 7.1.3. ICON
    • 7.1.4. Theorem Clinical Research
    • 7.1.5. PAREXEL
    • 7.1.6. Intrials
    • 7.1.7. Eurotrials
    • 7.1.8. PGS Medical/Statistics
    • 7.1.9. INC Research
    • 7.1.10. Chiltern
    • 7.1.11. Covance
    • 7.1.12. Quintiles

8. Emerging Pharmaceutical Market: Brazil - Appendix

  • 8.1. Market Definitions
  • 8.2. Abbreviations
  • 8.3. Sources
  • 8.4. Research Methodology
    • 8.4.1. Industry Performance
    • 8.4.2. Macroeconomic Environment
    • 8.4.3. Healthcare Regulations
    • 8.4.4. Industry Trends
  • 8.5. Contact Us
  • 8.6. Disclaimer

List of Tables

  • Table 1: Emerging Pharmaceutical Market: Brazil, Revenue, $bn, 2004-2011
  • Table 2: Emerging Pharmaceutical Market: Brazil, Revenue Forecasts, $bn, 2011-2018
  • Table 3: Emerging Pharmaceutical Market: Brazil, Population Age Structure, (%) ,1950-2050
  • Table 4: Emerging Pharmaceutical Market in Brazil, Population Forecast of Brazil, (Million), 2005-2050
  • Table 5: Emerging Pharmaceutical Market: Brazil, Number of Deaths by Major Diseases, (%), 2008
  • Table 6: Emerging Pharmaceutical Market: Brazil, Population Forecast for HIV/AIDS Prevalence ('000), 2011-2018
  • Table 7: Emerging Pharmaceutical Market: Brazil, Population Forecast for CVD Prevalence (Million), 2011-2018
  • Table 8: Emerging Pharmaceutical Market: Brazil, Population Forecast for Diabetes Prevalence (Million), 2011-2018
  • Table 9: Emerging Pharmaceutical Market: Brazil, Population Forecast for Cancer Prevalence ('000), 2011-2018
  • Table 10: Emerging Pharmaceutical Market: Brazil, GDP Results at Market Prices from 1Q-2010 to 1Q- 2011
  • Table 11: Emerging Pharmaceutical Market: Brazil, Per Capita Income, ($), 2000-2011
  • Table 12: Emerging Pharmaceutical Market: Brazil, Comparative Analysis of Healthcare Expenditure Ratios, Argentina, Mexico and BRIC Countries (%), 2010
  • Table 13: Emerging Pharmaceutical Market: Brazil, Public and Private Distribution, (%), 2008
  • Table 14: Emerging Pharmaceutical Market: Brazil, Healthcare Infrastructure, 2008
  • Table 15: Emerging Pharmaceutical Market - Brazil, Documents Required for Product Registration by ANVISA
  • Table 16: Emerging Pharmaceutical Market - Brazil, Clinical Trials Market, ($m), 2011-2018
  • Table 17: Emerging Pharmaceutical Market - Brazil, Number of Plan Members and Revenue, ($bn), 2011
  • Table 18: Emerging Pharmaceutical Market - Brazil, Private Healthcare Coverage Providers, Number of Plan Members and Revenue, (R $m), 2011
  • Table 19: Emerging Pharmaceutical Market - Brazil, Surgeries, Cost Comparison, the US and Brazil ($), 2009
  • Table 20: Emerging Pharmaceutical Market - Brazil, Recent M&A Deals, 2009-2011
  • Table 21: Emerging Pharmaceutical Market - Brazil, Recent Co-development Deals, 2011
  • Table 22: Emerging Pharmaceutical Market - Brazil, Recent Licensing Agreements, 2011

List of Figures

  • Figure 3: Emerging Pharmaceutical Market: Brazil, Revenue Forecast, $bn, 2004-2018
  • Figure 4: Emerging Pharmaceutical Market: Brazil, Market Share by Therapy Area, (%), 2010
  • Figure 5: Emerging Pharmaceutical Market: Brazil, R&D Restructuring Activities, 2011
  • Figure 6: Emerging Pharmaceutical Market - Brazil, Key Domestic Players, EMS Sigma Pharma , SWOT Profile, 2011
  • Figure 7: Emerging Pharmaceutical Market - Brazil, Key Domestic Players, Ache Laboratorios Farmaceuticos, SWOT Profile, 2011
  • Figure 8: Emerging Pharmaceutical Market - Brazil, Key Domestic Players, Eurofarma, SWOT Profile, 2011
  • Figure 9: Emerging Pharmaceutical Market - Brazil, Key Domestic Players, Medley Pharmaceuticals, SWOT Profile, 2011
  • Figure 10: Emerging Pharmaceutical Market - Brazil, Key Domestic Players, Hypermarcas, SWOT Profile, 2011
  • Figure 11: Emerging Pharmaceutical Market - Brazil, Key Foreign Players, Sanofi, SWOT Profile, 2011
  • Figure 12: Emerging Pharmaceutical Market - Brazil, Key Foreign Players, Novartis, SWOT Profile, 2011
  • Figure 13: Emerging Pharmaceutical Market - Brazil, Key Foreign Players, Pfizer, SWOT Profile, 2011
  • Figure 14: Emerging Pharmaceutical Market - Brazil, Key Foreign Players, Roche, SWOT Profile, 2011
  • Figure 15: Emerging Pharmaceutical Market: Brazil, Drivers and Barriers in the Brazilian Pharmaceutical Market
  • Figure 16: Emerging Pharmaceutical Market: Brazil, Healthcare Delivery Opportunities, 2011
  • Figure 17: Emerging Pharmaceutical Market: Brazil, Healthcare Delivery Barriers, 2011
  • Figure 18: Emerging Pharmaceutical Market: Brazil, PESTLE Analysis
  • Figure 19: Emerging Pharmaceutical Market: Brazil, Population Age Structure, (%), 1950-2050
  • Figure 20: Emerging Pharmaceutical Market: Brazil, Health Indicators, 2011
  • Figure 21: Emerging Pharmaceutical Market in Brazil, Population Forecast of Brazil, (Million), 2005-2050
  • Figure 22: Emerging Pharmaceutical Market: Brazil, Number of Deaths by Major Diseases, (%), 2008
  • Figure 23: Emerging Pharmaceutical Market: Brazil, Population Forecast for HIV/AIDS Prevalence ('000), 2011-2018
  • Figure 24: Emerging Pharmaceutical Market: Brazil, Population Forecast for CVD Prevalence (Million), 2011-2018
  • Figure 25: Emerging Pharmaceutical Market: Brazil, Population Forecast for Diabetes Prevalence (Million), 2011-2018
  • Figure 26: Emerging Pharmaceutical Market: Brazil, Population Forecast for Cancer Prevalence ('000), 2011-2018
  • Figure 27: Emerging Pharmaceutical Market: Brazil, GDP Composition by Sector (%), 2011
  • Figure 28: Emerging Pharmaceutical Market: Brazil, GDP and Inflation Rates, 2005-2011
  • Figure 29: Emerging Pharmaceutical Market: Brazil, National Healthcare Expenditure, (% of GDP), 2010
  • Figure 30: Emerging Pharmaceutical Market: Brazil, Comparative Analysis of Healthcare Expenditure Ratios, Argentina, Mexico and BRIC Countries, (%), 2010
  • Figure 31: Emerging Pharmaceutical Market: Brazil, Public and Private Distribution, (%), 2008
  • Figure 32: Emerging Pharmaceutical Market: Brazil, Healthcare Infrastructure, 2008
  • Figure 33: Emerging Pharmaceutical Market: Brazil, Healthcare Professionals, (%), 2008
  • Figure 34: Emerging Pharmaceutical Market: Brazil, Hospitals, by Bed Distribution, (%), 2008
  • Figure 35: Emerging Pharmaceutical Market: Brazil, Regulatory Approval Process for Clinical Trials
  • Figure 36: Emerging Pharmaceutical Market: Brazil, Drug Registration Process by ANVISA
  • Figure 37: Emerging Pharmaceutical Market - Brazil, Clinical Trial Market, ($m), 2011-2018
  • Figure 38: Emerging Pharmaceutical Market - Brazil, Reimbursement, 2011
  • Figure 39: Emerging Pharmaceutical Market - Brazil, Healthcare Coverage Providers, Plan Members, (%), 2010
  • Figure 40: Emerging Pharmaceutical Market - Brazil, Healthcare Coverage Providers, Revenue, (%), 2011
  • Figure 41: Emerging Pharmaceutical Market - Brazil, M&A Deals by Year, 2004-2011
  • Figure 42: Emerging Pharmaceutical Market - Brazil, M&A Deals by Value, (%), 2004-2011
  • Figure 43: Emerging Pharmaceutical Market - Brazil, Co-development Deals by Year, 2004-2011
  • Figure 44: Emerging Pharmaceutical Market - Brazil, Co-development Deals by Value, (%), 2004-2011
  • Figure 45: Emerging Pharmaceutical Market - Brazil, Licensing Agreements by Year, 2004-2011
  • Figure 46: Emerging Pharmaceutical Market - Brazil, Licensing Agreements by Value, (%), 2004-2011
  • Figure 47: Emerging Pharmaceutical Market - Brazil, PPD, Company Profile, 2011
  • Figure 48: Emerging Pharmaceutical Market - Brazil, PRA International, Company Profile, 2011
  • Figure 49: Emerging Pharmaceutical Market - Brazil, ICON, Company Profile, 2011
  • Figure 50: Emerging Pharmaceutical Market - Brazil, Theorem Clinical Research, Company Profile, 2011
  • Figure 51: Emerging Pharmaceutical Market - Brazil, PAREXEL, Company Profile, 2011
  • Figure 52: Emerging Pharmaceutical Market - Brazil, Intrials, Company Profile, 2011
  • Figure 53: Emerging Pharmaceutical Market - Brazil, Eurotrials, Company Profile, 2011
  • Figure 54: Emerging Pharmaceutical Market - Brazil, PGS Medical/Statistics, Company Profile, 2011
  • Figure 55: Emerging Pharmaceutical Market - Brazil, INC Research, Company Profile, 2011
  • Figure 56: Emerging Pharmaceutical Market - Brazil, Chiltern, Company Profile, 2011
  • Figure 57: Emerging Pharmaceutical Market - Brazil, Covance, Company Profile, 2011
  • Figure 58: Emerging Pharmaceutical Market - Brazil, Quintiles, Company Profile, 2011
Back to Top